初探山苦瓜萃取物之雄激素受體調節相關活性

An Initial Study on the Selective Androgen Receptor Modulator Related Activities of Wild Bitter Gourd

10.6342/NTU201702199

劉又禎

山苦瓜 ； 雄激素 ； 雄激素受體 ； 選擇性雄激素受體調節劑 ； 雄激素依賴型攝護腺癌細胞LNCaP ； wild bitter gourd ； androgen ； androgen receptor ； selective androgen receptor modulators (SARMs) ； androgen-dependent prostate cancer cell LNCaP

臺灣大學生化科技學系學位論文

2017年

碩士

黃青真

繁體中文

老年男性體內雄激素下降造成骨骼肌逐漸退化並流失，但補充雄激素以提升肌肉質量及肌力，則可能伴隨攝護腺癌發生的風險。攝護腺癌的發生主要與年齡有關，而遺傳或是飲食所致肥胖也是罹患攝護腺癌的潛在危險因子。攝護腺的生長由雄激素及其受體調節，而此路徑也被認為與攝護腺癌化有關。以雄激素阻斷療法 (androgen-deprivation therapy, ADT)可以控制攝護腺癌細胞生長，但雄激素缺乏可能影響肌肉功能。若以選擇性雄激素受體調節劑 (selective androgen receptor modulators, SARMs)作為治療藥物則能夠選擇性的抑制攝護腺癌細胞生長且不影響肌肉質量。 苦瓜 (Momordica charantoa L.)被認為具有治療攝護腺癌的潛力。而其所含三萜類化合物以不帶醣基的形式促進細胞葡萄糖汲取之活性最高。本實驗室先前研究觀察到山苦瓜萃取物可調節雄激素受體轉錄活性，擬進一步探討其是否具有類似「選擇性雄激素受體調節劑 (Selective Androgen Receptor Modulator, SARM)」之特性。故本實驗以不同溫度對多種品系之山苦瓜進行水解再以乙酸乙酯萃取得低極性之活性物質，觀察其為SARM之可能性。 實驗結果，比較各品系山苦瓜及其水解產物之萃取物，山苦瓜P81品系50℃水解產物之乙酸乙酯萃取物 (P81 50℃hEAE)調節雄激素受體轉錄活性最佳。於50 µg/mL時能夠顯著的提高28.0%之AR轉錄活性，在有10 nM 5α-DHT共同處理之下能夠抑制其30.2%之轉錄活性，似為partial agonist符合SARMs之特徵。而200 µg/mL之P81 50℃hEAE抑制21.1%的雄激素依賴型攝護腺癌細胞LNCaP增生，共同處理0.1及10 nM 5α-DHT之下則分別抑制24.8%及33.6%的LNCaP增生，故在攝護腺癌細胞中為antagonist並同樣符合SARMs的特性。另外，共同處理bicalutamide以阻擋AR的結合位，則可部分挽回200 µg/mL P81 50℃hEAE抑制增生的效果，顯示該抑制作用應涉及AR之調控。而P81 50℃hEAE在有無共同處理0.1 nM 5α-DHT之下，皆使LNCaP之細胞週期停滯在G0/G1 phase並降低細胞遷移的能力，且可抑制該細胞中雄激素受體相關基因KLK3、IGF-1及IGF-1R的表現。在餵食高脂或高脂添加4%山苦瓜粉末飲食四週之C57BL/6J小鼠實驗中，雄激素相關組織攝護腺及提肛肌之重量與該組織中雄激素受體調節基因之表現量並未受到飲食處理有顯著影響。 根據以上實驗結果，P81 50℃hEAE可調節雄激素受體轉錄活性，但於雄激素依賴型攝護腺癌細胞又抑制其生長及雄激素下游之基因表現。故初步判定山苦瓜具有SARMs之特質。

Decreased androgen associated with aging is considered one of the causes of sarcopenia. Androgen replacement can rescue the skeletal muscle mass and function, but may increase risk of prostate cancer. Prostate cancer develops mainly in senior men, but family history and diet-caused obesity are also risk factors of prostate cancer. Normal development of the prostate is dependent on androgen acting through the androgen receptor, and androgen remains important in the progression of prostate cancer. Androgen deprivation therapy (ADT) reduces levels of androgen and discontinue its effect on prostate cancer cells, but androgen deficiency may lead to decline in skeletal muscle function. In this regards, selective androgen receptor modulators (SARMs) have been developed as therapeutics that can selectively inhibit prostate cancer cell growth but maintain skeletal muscle mass. It has been reported that bitter gourd (Momordica charantoa L., BG) inhibited growth of prostate cancer cells. Preliminary data in our laboratory showed that the ethyl acetate extract (EAE) wild bitter gourd (WBG) modulated the androgen receptor transactivation activity. This study aims to investigate the potential of the WBG EAE as selective androgen receptor modulator (SARM). EAEs of various cultivars of the WBG and hydrolyzed WBG were examined and compared. Among WBG cultivars tested, the EAE of the 50℃ hydrolyzed P81 (P81 50℃hEAE) showed highest effect on modulating the androgen receptor transactivation activity. Acting as a partial agonist, 50 µg/mL of P81 50℃hEAE significantly increased 28.0% of the AR transactivation activity but suppressed 30.2% of the transactivation activity of 10 nM 5α-DHT when co-treated. In the androgen-dependent prostate cancer cell LNCaP, 200 µg/mL P81 50℃hEAE showed 21.1% inhibition on cell proliferation. In the presence of 0.1 or 10 nM 5α-DHT, there were 24.8% or 33.6% inhibition in the LNCaP proliferation. In LNCaP cells, P81 50℃hEAE acted as an antagonist, in line with the features of SARMs. Moreover, co-treatment with bicalutamide partially recovered the inhibition effect of 200 µg/mL P81 50℃hEAE on LNCaP cells proliferation, suggested that the inhibition of P81 50℃hEAE is related to AR. Moreover, P81 50℃hEAE induced cell growth arrest in the G0/G1 phase, impaired the migration and down-regulated the expressions of androgen receptor related genes, KLK3, IGF-1 and IGF-1R either in the absence or presence of 0.1 nM 5α-DHT. Groups of C57BL/6J mice were fed a high fat diet or 4% WBG supplemented high fat diets for four weeks. Tissue weights and the mRNA expressions of androgen receptor target genes of androgen-sensitive tissues, prostate and levator ani muscle, were not significantly different among groups (p>0.05). In conclusion, P81 50℃hEAE can modulate the androgen receptor activity, inhibit LNCaP cell growth and androgen receptor related genes expression. It is speculated that WBG might have health benefit as SARMs.

1. Agus, D. B., Cordon-Cardo, C., Fox, W., Drobnjak, M., Koff, A., Golde, D. W., et al. (1999). Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst, 91(21), 1869-1876.
   連結：
2. Akhmedov, D., & Berdeaux, R. (2013). The effects of obesity on skeletal muscle regeneration. Frontiers in Physiology, 4.
   連結：
3. Albrecht, M., Jiang, W., Kumi-Diaka, J., Lansky, E. P., Gommersall, L. M., Patel, A., et al. (2004). Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food, 7(3), 274-283.
   連結：
4. Alfred Sherwood Romer, T. S. P. (1977). The vertebrate body. Philadelphia, PA: Holt-Saunders International, pp. 394-395.
   連結：
5. Ali, S., & Garcia, J. M. (2014). Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology, 60(4), 294-305.
   連結：
6. Amling, C. L. (2005). Relationship between obesity and prostate cancer. Curr Opin Urol, 15(3), 167-171.
   連結：
7. Arnold, J. T., Le, H., McFann, K. K., & Blackman, M. R. (2005). Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab, 288(3), E573-584.
   連結：
8. Auvinen, M., Paasinen, A., Andersson, L. C., & Holtta, E. (1992). Ornithine Decarboxylase Activity Is Critical for Cell-Transformation. Nature, 360(6402), 355-358.
   連結：
9. Azad, A. A., Zoubeidi, A., Gleave, M. E., & Chi, K. N. (2015). Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat Rev Urol, 12(1), 26-36.
   連結：
10. Bai, V. U., Cifuentes, E., Menon, M., Barrack, E. R., & Reddy, G. P. (2005). Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase. J Cell Physiol, 204(2), 381-387.
    連結：
11. Balk, S. P. (2002). Androgen receptor as a target in androgen-independent prostate cancer. Urology, 60(3a), 132-138.
    連結：
12. Balk, S. P., & Knudsen, K. E. (2008). AR, the cell cycle, and prostate cancer. Nucl Recept Signal, 6, e001.
    連結：
13. Baracat, E., Haidar, M., Lopez, F. J., Pickar, J., Dey, M., & Negro-Vilar, A. (1999). Estrogen activity and novel tissue selectivity of delta8,9-dehydroestrone sulfate in postmenopausal women. J Clin Endocrinol Metab, 84(6), 2020-2027.
    連結：
14. Barry, M. J. (1990). Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am, 17(3), 495-507.
    連結：
15. Basch, E., Gabardi, S., & Ulbricht, C. (2003b). Bitter melon (Momordica charantia): A review of efficacy and safety. American Journal of Health-System Pharmacy, 60(4), 356-359.
    連結：
16. Bhattacharya, A., Banu, J., Rahman, M., Causey, J., & Fernandes, G. (2006). Biological effects of conjugated linoleic acids in health and disease. Journal of Nutritional Biochemistry, 17(12), 789-810.
    連結：
17. Bratt, O., Kristoffersson, U., Lundgren, R., & Olsson, H. (1997). The risk of malignant tumours in first-degree relatives of men with early onset prostate cancer: A population-based cohort study. European Journal of Cancer, 33(13), 2237-2240.
    連結：
18. Bruckheimer, E. M., Spurgers, K., Weigel, N. L., Logothetis, C., & McDonnell, T. J. (2003). Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol, 169(4), 1553-1557.
    連結：
19. Buachan, P., Chularojmontri, L., & Wattanapitayakul, S. K. (2014). Selected activities of Citrus maxima Merr. fruits on human endothelial cells: enhancing cell migration and delaying cellular aging. Nutrients, 6(4), 1618-1634.
    連結：
20. Cai, L. Q., Cai, J., Wu, W., & Zhu, Y. S. (2011a). 17alpha-Estradiol and genistein inhibit high fat diet induced prostate gene expression and prostate growth in the rat. J Urol, 186(4), 1489-1496.
    連結：
21. Cai, L. Q., Cai, J. J., Wu, W. D., & Zhu, Y. S. (2011b). 17 alpha-Estradiol and Genistein Inhibit High Fat Diet Induced Prostate Gene Expression and Prostate Growth in the Rat. Journal of Urology, 186(4), 1489-1496.
    連結：
22. Cai, L. Q., Imperato-McGinley, J., & Zhu, Y. S. (2006). Regulation of prostate 5alpha-reductase-2 gene expression and prostate weight by dietary fat and caloric intake in the rat. Prostate, 66(7), 738-748.
    連結：
23. Carter, B. S., Bova, G. S., Beaty, T. H., Steinberg, G. D., Childs, B., Isaacs, W. B., et al. (1993). Hereditary Prostate-Cancer - Epidemiologic and Clinical-Features. Journal of Urology, 150(3), 797-802.
    連結：
24. Casella, R., Bubendorf, L., Schaefer, D. J., Bachmann, A., Gasser, T. C., & Sulser, T. (2005). Does the prostate really need androgens to grow? Transurethral resection of the prostate in a male-to-female transsexual 25 years after sex-changing operation. Urologia Internationalis, 75(3), 288-290.
    連結：
25. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., et al. (1994). Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol, 151(5), 1283-1290.
    連結：
26. Chan, J. M., Stampfer, M. J., & Giovannucci, E. L. (1998). What causes prostate cancer? A brief summary of the epidemiology. Semin Cancer Biol, 8(4), 263-273.
    連結：
27. Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., et al. (2011). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget, 2(3), 135-164.
    連結：
28. Charles Huggins, W. W. S., J. Henry Heinen (1942). Chemical composition of human semen and of the secretions of the prostate and seminal vehicles. Am J Physiol., 136 (133): 467-473.
    連結：
29. Chaturvedi, P. (2012). Antidiabetic potentials of Momordica charantia: multiple mechanisms behind the effects. J Med Food, 15(2), 101-107.
    連結：
30. Chen, J., Tian, R., Qiu, M., Lu, L., Zheng, Y., & Zhang, Z. (2008). Trinorcucurbitane and cucurbitane triterpenoids from the roots of Momordica charantia. Phytochemistry, 69(4), 1043-1048.
    連結：
31. Chen, J. C., Liu, W. Q., Lu, L., Qiu, M. H., Zheng, Y. T., Yang, L. M., et al. (2009). Kuguacins F-S, cucurbitane triterpenoids from Momordica charantia. Phytochemistry, 70(1), 133-140.
    連結：
32. Cheng, Z. X., Sun, B., Wang, S. J., Gao, Y., Zhang, Y. M., Zhou, H. X., et al. (2011). Nuclear factor-kappaB-dependent epithelial to mesenchymal transition induced by HIF-1alpha activation in pancreatic cancer cells under hypoxic conditions. PLoS One, 6(8), e23752.
    連結：
33. Christopoulos, A. (2002). Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov, 1(3), 198-210.
    連結：
34. Chularojmontri, L., Suwatronnakorn, M., & Wattanapitayakul, S. K. (2013). Phyllanthus emblica L. Enhances Human Umbilical Vein Endothelial Wound Healing and Sprouting. Evid Based Complement Alternat Med, 2013, 720728.
    連結：
35. Cifuentes, E., Croxen, R., Menon, M., Barrack, E. R., & Reddy, G. P. (2003). Synchronized prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 into S phase. J Cell Physiol, 195(3), 337-345.
    連結：
36. Cleutjens, K. B., van der Korput, H. A., van Eekelen, C. C., van Rooij, H. C., Faber, P. W., & Trapman, J. (1997). An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol, 11(2), 148-161.
    連結：
37. Cohen, P., Peehl, D. M., & Rosenfeld, R. (1998). Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer, 78(4), 554-556.
    連結：
38. Crozat, A., Palvimo, J. J., Julkunen, M., & Janne, O. A. (1992). Comparison of androgen regulation of ornithine decarboxylase and S-adenosylmethionine decarboxylase gene expression in rodent kidney and accessory sex organs. Endocrinology, 130(3), 1131-1144.
    連結：
39. Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., et al. (2010). Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing, 39(4), 412-423.
    連結：
40. Davison, S. L., & Bell, R. (2006). Androgen physiology. Semin Reprod Med, 24(2), 71-77.
    連結：
41. De Jesus-Tran, K. P., Cote, P. L., Cantin, L., Blanchet, J., Labrie, F., & Breton, R. (2006). Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Science, 15(5), 987-999.
    連結：
42. Dehm, S. M., & Tindall, D. J. (2006). Molecular regulation of androgen action in prostate cancer. J Cell Biochem, 99(2), 333-344.
    連結：
43. Denmeade, S. R., Lin, X. S., & Isaacs, J. T. (1996). Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28(4), 251-265.
    連結：
44. Diamandis, E. P., Yousef, G. M., & Olsson, A. Y. (2004). An update on human and mouse glandular kallikreins. Clin Biochem, 37(4), 258-260.
    連結：
45. Dilzer, A., & Park, Y. (2012). Implication of conjugated linoleic acid (CLA) in human health. Crit Rev Food Sci Nutr, 52(6), 488-513.
    連結：
46. Dubois, V., Laurent, M. R., Sinnesael, M., Cielen, N., Helsen, C., Clinckemalie, L., et al. (2014). A satellite cell-specific knockout of the androgen receptor reveals myostatin as a direct androgen target in skeletal muscle. FASEB J, 28(7), 2979-2994.
    連結：
47. Edwards, J., & Bartlett, J. M. (2005). The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int, 95(9), 1327-1335.
    連結：
48. Fang, E. F., & Ng, T. B. (2011). Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties. Curr Mol Med, 11(5), 417-436.
    連結：
49. Feldman, B. J., & Feldman, D. (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer, 1(1), 34-45.
    連結：
50. Ferrando, A. A., Sheffield-Moore, M., Yeckel, C. W., Gilkison, C., Jiang, J., Achacosa, A., et al. (2002). Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab, 282(3), E601-607.
    連結：
51. Florini, J. R., Ewton, D. Z., & Coolican, S. A. (1996). Growth hormone and the insulin-like growth factor system in myogenesis. Endocrine Reviews, 17(5), 481-517.
    連結：
52. Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., et al. (1991). E-Cadherin-Mediated Cell Cell-Adhesion Prevents Invasiveness of Human Carcinoma-Cells. Journal of Cell Biology, 113(1), 173-185.
    連結：
53. Galofre, J. C., Chacon, A. M., & Latif, R. (2013). Targeting thyroid diseases with TSH receptor analogs. Endocrinol Nutr, 60(10), 590-598.
    連結：
54. Gao, W., Bohl, C. E., & Dalton, J. T. (2005). Chemistry and structural biology of androgen receptor. Chem Rev, 105(9), 3352-3370.
    連結：
55. Gao, W. Q., & Dalton, J. T. (2007). Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discovery Today, 12(5-6), 241-248.
    連結：
56. Gelmann, E. P. (2002). Molecular biology of the androgen receptor. Journal of Clinical Oncology, 20(13), 3001-3015.
    連結：
57. Giovannucci, E., Rimm, E. B., Colditz, G. A., Stampfer, M. J., Ascherio, A., Chute, C. G., et al. (1993). A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst, 85(19), 1571-1579.
    連結：
58. Giovannucci, E., Rimm, E. B., Liu, Y., Leitzmann, M., Wu, K., Stampfer, M. J., et al. (2003). Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst, 95(16), 1240-1244.
    連結：
59. Gittes, R. F. (1991). Carcinoma of the prostate. N Engl J Med, 324(4), 236-245.
    連結：
60. Glass, D. J. (2010). PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr Top Microbiol Immunol, 346, 267-278.
    連結：
61. Grimberg, A. (2003). Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther, 2(6), 630-635.
    連結：
62. Grover, J. K., & Yadav, S. P. (2004). Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol, 93(1), 123-132.
    連結：
63. Guevara-Aguirre, J., Balasubramanian, P., Guevara-Aguirre, M., Wei, M., Madia, F., Cheng, C. W., et al. (2011). Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans. Science Translational Medicine, 3(70).
    連結：
64. Guo, Y., Pili, R., & Passaniti, A. (1994). Regulation of prostate-specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix. Prostate, 24(1), 1-10.
    連結：
65. Ha, Y. L., Grimm, N. K., & Pariza, M. W. (1987). Anticarcinogens from Fried Ground-Beef - Heat-Altered Derivatives of Linoleic-Acid. Carcinogenesis, 8(12), 1881-1887.
    連結：
66. Harfmann, B. D., Schroder, E. A., & Esser, K. A. (2015). Circadian rhythms, the molecular clock, and skeletal muscle. J Biol Rhythms, 30(2), 84-94.
    連結：
67. Heinlein, C. A., & Chang, C. (2002). Androgen receptor (AR) coregulators: an overview. Endocr Rev, 23(2), 175-200.
    連結：
68. Heinlein, C. A., & Chang, C. (2004). Androgen receptor in prostate cancer. Endocr Rev, 25(2), 276-308.
    連結：
69. Hennessy, A. A., Ross, R. P., Devery, R., & Stanton, C. (2011). The health promoting properties of the conjugated isomers of alpha-linolenic acid. Lipids, 46(2), 105-119.
    連結：
70. Hershberger, L. G., Shipley, E. G., & Meyer, R. K. (1953). Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med, 83(1), 175-180.
    連結：
71. Hickson, R. C., Kurowski, T. T., Galassi, T. M., Daniels, D. G., & Chatterton, R. J., Jr. (1985). Androgen cytosol binding during compensatory overload-induced skeletal muscle hypertrophy. Can J Biochem Cell Biol, 63(5), 348-354.
    連結：
72. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348(6299), 334-336.
    連結：
73. Hopkins, A. L., & Groom, C. R. (2002). The druggable genome. Nat Rev Drug Discov, 1(9), 727-730.
    連結：
74. Hotte, S. J., & Saad, F. (2010). Current management of castrate-resistant prostate cancer. Current Oncology, 17, S72-S79.
    連結：
75. Hu, Z. Y., Wang, H. L., Lee, I. H., Modi, S., Wang, X. A., Du, J., et al. (2010). PTEN Inhibition Improves Muscle Regeneration in Mice Fed a High-Fat Diet. Diabetes, 59(6), 1312-1320.
    連結：
76. Huggins, C., & Hodges, C. V. (1972). Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin, 22(4), 232-240.
    連結：
77. Huttenlocher, A., & Horwitz, A. R. (2011). Integrins in cell migration. Cold Spring Harb Perspect Biol, 3(9), a005074.
    連結：
78. Iglesias-Gato, D., Chuan, Y. C., Wikstrom, P., Augsten, S., Jiang, N., Niu, Y. J., et al. (2014). SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis, 35(1), 24-33.
    連結：
79. Isaacs, J. T., & Coffey, D. S. (1989). Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl, 2, 33-50.
    連結：
80. Johansen, K. L. (2004). Testosterone metabolism and replacement therapy in patients with end-stage renal disease. Semin Dial, 17(3), 202-208.
    連結：
81. Kaaks, R., & Stattin, P. (2010). Obesity, endogenous hormone metabolism, and prostate cancer risk: a conundrum of "highs" and "lows". Cancer Prev Res (Phila), 3(3), 259-262.
    連結：
82. Kaku, K., Fiedorek, F. T., Jr., Province, M., & Permutt, M. A. (1988). Genetic analysis of glucose tolerance in inbred mouse strains. Evidence for polygenic control. Diabetes, 37(6), 707-713.
    連結：
83. Kang, H. Y., Tsai, M. Y., Chang, C., & Huang, K. E. (2003). Mechanisms and clinical relevance of androgens and androgen receptor actions. Chang Gung Med J, 26(6), 388-402.
    連結：
84. Kazmin, D., Prytkova, T., Cook, C. E., Wolfinger, R., Chu, T. M., Beratan, D., et al. (2006). Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol Endocrinol, 20(6), 1201-1217.
    連結：
85. Keller, E. T., Ershler, W. B., & Chang, C. (1996). The androgen receptor: a mediator of diverse responses. Front Biosci, 1, d59-71.
    連結：
86. Kemppainen, J. A., Langley, E., Wong, C. I., Bobseine, K., Kelce, W. R., & Wilson, E. M. (1999). Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol, 13(3), 440-454.
    連結：
87. Kenakin, T. (2004). Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol, 65(1), 2-11.
    連結：
88. Key, T. J., Silcocks, P. B., Davey, G. K., Appleby, P. N., & Bishop, D. T. (1997). A case-control study of diet and prostate cancer. Br J Cancer, 76(5), 678-687.
    連結：
89. Knudsen, K. E., Arden, K. C., & Cavenee, W. K. (1998). Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem, 273(32), 20213-20222.
    連結：
90. Kobori, M., Ohnishi-Kameyama, M., Akimoto, Y., Yukizaki, C., & Yoshida, M. (2008). Alpha-eleostearic acid and its dihydroxy derivative are major apoptosis-inducing components of bitter gourd. J Agric Food Chem, 56(22), 10515-10520.
    連結：
91. Krieger, J. N., Nyberg, L., Jr., & Nickel, J. C. (1999). NIH consensus definition and classification of prostatitis. JAMA, 282(3), 236-237.
    連結：
92. Kristal, A. R., Arnold, K. B., Schenk, J. M., Neuhouser, M. L., Weiss, N., Goodman, P., et al. (2007). Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol, 177(4), 1395-1400; quiz 1591.
    連結：
93. Kritchevsky, D. (1995). Fatty-Acids, Triglyceride Structure, and Lipid-Metabolism. Journal of Nutritional Biochemistry, 6(4), 172-178.
    連結：
94. Krongrad, A., Wilson, C. M., Wilson, J. D., Allman, D. R., & McPhaul, M. J. (1991). Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol, 76(1-3), 79-88.
    連結：
95. Kumar, R. J., Barqawi, A., & Crawford, E. D. (2005). Adverse events associated with hormonal therapy for prostate cancer. Rev Urol, 7 Suppl 5, S37-43.
    連結：
96. Kunkel, S. D., Suneja, M., Ebert, S. M., Bongers, K. S., Fox, D. K., Malmberg, S. E., et al. (2011). mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab, 13(6), 627-638.
    連結：
97. Labrie, F., Luu-The, V., Labrie, C., & Simard, J. (2001). DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Frontiers in Neuroendocrinology, 22(3), 185-212.
    連結：
98. Le, H., Arnold, J. T., McFann, K. K., & Blackman, M. R. (2006). DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab, 290(5), E952-960.
    連結：
99. Lee, C., Sutkowski, D. M., Sensibar, J. A., Zelner, D., Kim, I., Amsel, I., et al. (1995). Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology, 136(2), 796-803.
    連結：
100. Lee, D. K. (2002). Androgen receptor enhances myogenin expression and accelerates differentiation. Biochem Biophys Res Commun, 294(2), 408-413.
     連結：
101. Lee, N. K. L., & Maclean, H. E. (2011). Polyamines, Androgens, and Skeletal Muscle Hypertrophy. Journal of Cellular Physiology, 226(6), 1453-1460.
     連結：
102. Lee, S. J. (2004). Regulation of muscle mass by myostatin. Annual Review of Cell and Developmental Biology, 20, 61-86.
     連結：
103. Li, H. Z., Ahonen, T. J., Alanen, K., Xie, J. W., LeBaron, M. J., Pretlow, T. G., et al. (2004). Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Research, 64(14), 4774-4782.
     連結：
104. Li, X., Song, Y., Zhang, P., Zhu, H., Chen, L., Xiao, Y., et al. (2016). Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway. Tumour Biol, 37(6), 7599-7613.
     連結：
105. Lilja, H. (1985). A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest, 76(5), 1899-1903.
     連結：
106. Liu, Y. N., Liu, Y., Lee, H. J., Hsu, Y. H., & Chen, J. H. (2008). Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol, 28(23), 7096-7108.
     連結：
107. Lu, X., Law, B. K., Chytil, A. M., Brown, K. A., Aakre, M. E., & Moses, H. L. (2004). Activation of the Erk pathway is required for TGF-beta 1-induced EMT in vitro. Neoplasia, 6(5), 603-610.
     連結：
108. MacLean, H. E., Chiu, W. S. M., Notini, A. J., Axell, A. M., Davey, R. A., McManus, J. F., et al. (2008). Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. Faseb Journal, 22(8), 2676-2689.
     連結：
109. MacLean, H. E., Warne, G. L., & Zajac, J. D. (1997). Localization of functional domains in the androgen receptor. Journal of Steroid Biochemistry and Molecular Biology, 62(4), 233-242.
     連結：
110. Makinen, T., Tammela, T. L., Stenman, U. H., Maattanen, L., Rannikko, S., Aro, J., et al. (2002). Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol, 20(11), 2658-2663.
     連結：
111. Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., et al. (2000). Structural evidence for ligand specificity in the binding domain of the human androgen receptor - Implications for pathogenic gene mutations. Journal of Biological Chemistry, 275(34), 26164-26171.
     連結：
112. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412-419.
     連結：
113. May, L. T., Avlani, V. A., Sexton, P. M., & Christopoulos, A. (2004). Allosteric modulation of G protein-coupled receptors. Curr Pharm Des, 10(17), 2003-2013.
     連結：
114. Meng, Y., Lin, Z. M., Ge, N., Zhang, D. L., Huang, J., & Kong, F. (2015). Ursolic Acid Induces Apoptosis of Prostate Cancer Cells via the PI3K/Akt/mTOR Pathway. Am J Chin Med, 43(7), 1471-1486.
     連結：
115. Migliaccio, A., Castoria, G., Di Domenico, M., de Falco, A., Bilancio, A., Lombardi, M., et al. (2000). Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J, 19(20), 5406-5417.
     連結：
116. Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. (2013). An evolving understanding of nuclear receptor coregulator proteins. J Mol Endocrinol, 51(3), T23-36.
     連結：
117. Min, L., Yanase, T., Tanaka, T., Fan, W. Q., Nomura, M., Kawate, H., et al. (2009). A Novel Synthetic Androgen Receptor Ligand, S42, Works as a Selective Androgen Receptor Modulator and Possesses Metabolic Effects with Little Impact on the Prostate. Endocrinology, 150(12), 5606-5616.
     連結：
118. Mooradian, A. D., Morley, J. E., & Korenman, S. G. (1987). Biological actions of androgens. Endocr Rev, 8(1), 1-28.
     連結：
119. Mubiru, J. N., Garcia-Forey, M., Cavazos, N., Hemmat, P., Dick, E. J., Jr., Owston, M. A., et al. (2012). Serum prostate specific antigen changes in cynomolgus monkeys (Macaca fascicularis) on a high sugar high fat diet. Prostate, 72(5), 469-475.
     連結：
120. Munoz, J., Wheler, J. J., & Kurzrock, R. (2015). Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget, 6(2), 592-603.
     連結：
121. Murthy, S., Wu, M., Bai, V. U., Hou, Z., Menon, M., Barrack, E. R., et al. (2013). Role of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase. PLoS One, 8(2), e56692.
     連結：
122. Narayanan, R., Coss, C. C., Yepuru, M., Kearbey, J. D., Miller, D. D., & Dalton, J. T. (2008). Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol, 22(11), 2448-2465.
     連結：
123. Negro-Vilar, A. (1999). Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab, 84(10), 3459-3462.
     連結：
124. Norman, A. W., Mizwicki, M. T., & Norman, D. P. (2004). Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov, 3(1), 27-41.
     連結：
125. Oh, W. K., & Kantoff, P. W. (1998). Management of hormone refractory prostate cancer: current standards and future prospects. J Urol, 160(4), 1220-1229.
     連結：
126. Ohwaki, K., Endo, F., Kachi, Y., Hattori, K., Muraishi, O., Nishikitani, M., et al. (2012). Relationship between Dietary Factors and Prostate-Specific Antigen in Healthy Men. Urologia Internationalis, 89(3), 270-274.
     連結：
127. Olsson, A. Y., & Lundwall, A. (2002). Organization and evolution of the glandular kallikrein locus in Mus musculus. Biochem Biophys Res Commun, 299(2), 305-311.
     連結：
128. Pandini, G., Mineo, R., Frasca, F., Roberts, C. T., Marcelli, M., Vigneri, R., et al. (2005). Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Research, 65(5), 1849-1857.
     連結：
129. Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997). Cancer statistics, 1997. CA Cancer J Clin, 47(1), 5-27.
     連結：
130. Parkin, D. M., Pisani, P., & Ferlay, J. (1999). Global cancer statistics. Ca-a Cancer Journal for Clinicians, 49(1), 33-64.
     連結：
131. Pegg, A. E., & Mccann, P. P. (1982). Polyamine Metabolism and Function. American Journal of Physiology, 243(5), C212-C221.
     連結：
132. Petera, V., Bobek, K., & Lahn, V. (1962). Serum transaminase (GOT, GPT) and lactic dehydrogenase activity during treatment with methyl testosterone. Clin Chim Acta, 7, 604-606.
     連結：
133. Pitchakarn, P., Ogawa, K., Suzuki, S., Takahashi, S., Asamoto, M., Chewonarin, T., et al. (2010). Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Cancer Sci, 101(10), 2234-2240.
     連結：
134. Pitchakarn, P., Suzuki, S., Ogawa, K., Pompimon, W., Takahashi, S., Asamoto, M., et al. (2011). Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf. Cancer Lett, 306(2), 142-150.
     連結：
135. Pitchakarn, P., Suzuki, S., Ogawa, K., Pompimon, W., Takahashi, S., Asamoto, M., et al. (2012). Kuguacin J, a triterpeniod from Momordica charantia leaf, modulates the progression of androgen-independent human prostate cancer cell line, PC3. Food Chem Toxicol, 50(3-4), 840-847.
     連結：
136. Pulvirenti, L., & Koob, G. F. (2002). Being partial to psychostimulant addiction therapy. Trends in Pharmacological Sciences, 23(4), 151-153.
     連結：
137. Recouvreux MV, W. B., Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung LW, Melmed S. (2017). Androgen receptor regulation of local growth hormone in prostate cancer cells. Endocrine Society.
     連結：
138. Riegman, P. H., Vlietstra, R. J., van der Korput, J. A., Romijn, J. C., & Trapman, J. (1989). Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun, 159(1), 95-102.
     連結：
139. Rohrmann, S., Roberts, W. W., Walsh, P. C., & Platz, E. A. (2003). Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer. Prostate, 55(2), 140-146.
     連結：
140. Rose, D. P., Boyar, A. P., & Wynder, E. L. (1986). International Comparisons of Mortality-Rates for Cancer of the Breast, Ovary, Prostate, and Colon, and Per-Capita Food-Consumption. Cancer, 58(11), 2363-2371.
     連結：
141. Rosenson, R. S., Wright, R. S., Farkouh, M., & Plutzky, J. (2012). Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J, 164(5), 672-680.
     連結：
142. Ru, P., Steele, R., Nerurkar, P. V., Phillips, N., & Ray, R. B. (2011). Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev Res (Phila), 4(12), 2122-2130.
     連結：
143. Russell, D. W., & Wilson, J. D. (1994). Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem, 63, 25-61.
     連結：
144. Saad, F., & Gooren, L. J. (2011). The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes, 2011.
     連結：
145. Sabourin, L. A., & Rudnicki, M. A. (2000). The molecular regulation of myogenesis. Clinical Genetics, 57(1), 16-25.
     連結：
146. Sahlin, L., Norstedt, G., & Eriksson, H. (1994). Androgen regulation of the insulin-like growth factor-I and the estrogen receptor in rat uterus and liver. J Steroid Biochem Mol Biol, 51(1-2), 57-66.
     連結：
147. Sakuma, K., & Yamaguchi, A. (2012). Novel intriguing strategies attenuating to sarcopenia. J Aging Res, 2012, 251217.
     連結：
148. Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012). Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets, 16(1), 103-119.
     連結：
149. Sarikaya, S., Resorlu, M., Oguz, U., Yordam, M., Bozkurt, O. F., & Unsal, A. (2014). Evaluation of the pathologic results of prostate biopsies in terms of age, Gleason score and PSA level: our experience and review of the literature. Arch Ital Urol Androl, 86(4), 288-290.
     連結：
150. Schulman, C., & Lunenfeld, B. (2002). The ageing male. World J Urol, 20(1), 4-10.
     連結：
151. Segal, S., Narayanan, R., & Dalton, J. T. (2006). Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin Investig Drugs, 15(4), 377-387.
     連結：
152. Sekine, Y., Osei-Hwedieh, D., Matsuda, K., Raghavachari, N., Liu, D. L., Furuya, Y., et al. (2011). High Fat Diet Reduces the Expression of Glutathione Peroxidase 3 in Mouse Prostate. Prostate, 71(14), 1499-1509.
     連結：
153. Serra, C., Bhasin, S., Tangherlini, F., Barton, E. R., Ganno, M., Zhang, A. Q., et al. (2011). The Role of GH and IGF-I in Mediating Anabolic Effects of Testosterone on Androgen-Responsive Muscle. Endocrinology, 152(1), 193-206.
     連結：
154. Shand, R. L., & Gelmann, E. P. (2006). Molecular biology of prostate-cancer pathogenesis. Curr Opin Urol, 16(3), 123-131.
     連結：
155. Shih, C. C., Lin, C. H., Lin, W. L., & Wu, J. B. (2009). Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J Ethnopharmacol, 123(1), 82-90.
     連結：
156. Shih, C. C., Shlau, M. T., Lin, C. H., & Wu, J. B. (2014). Momordica charantia ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice. Phytother Res, 28(3), 363-371.
     連結：
157. Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer statistics, 2015. CA Cancer J Clin, 65(1), 5-29.
     連結：
158. Silva, S. A., Gobbo, M. G., Pinto-Fochi, M. E., Rafacho, A., Taboga, S. R., Almeida, E. A., et al. (2015). Prostate hyperplasia caused by long-term obesity is characterized by high deposition of extracellular matrix and increased content of MMP-9 and VEGF. International Journal of Experimental Pathology, 96(1), 21-30.
     連結：
159. Sitnick, M., Bodine, S. C., & Rutledge, J. C. (2009). Chronic high fat feeding attenuates load-induced hypertrophy in mice. Journal of Physiology-London, 587(23), 5753-5765.
     連結：
160. Spitz, M. R., Currier, R. D., Fueger, J. J., Babaian, R. J., & Newell, G. R. (1991). Familial Patterns of Prostate-Cancer - a Case-Control Analysis. Journal of Urology, 146(5), 1305-1307.
     連結：
161. Steers, W. D. (2001). 5alpha-reductase activity in the prostate. Urology, 58(6 Suppl 1), 17-24; discussion 24.
     連結：
162. Stenman, U. H. (1997). Prostate-specific antigen, clinical use and staging: An overview. British Journal of Urology, 79, 53-60.
     連結：
163. Stephenson, R. P. (1956). A modification of receptor theory. Br J Pharmacol Chemother, 11(4), 379-393.
     連結：
164. Stone, P., Hardy, J., Huddart, R., A'Hern, R., & Richards, M. (2000). Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer, 36(9), 1134-1141.
     連結：
165. Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., et al. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med, 336(20), 1401-1408.
     連結：
166. Sun, M., Yang, L., Feldman, R. I., Sun, X. M., Bhalla, K. N., Jove, R., et al. (2003). Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem, 278(44), 42992-43000.
     連結：
167. Surwit, R. S., Seldin, M. F., Kuhn, C. M., Cochrane, C., & Feinglos, M. N. (1991). Control of expression of insulin resistance and hyperglycemia by different genetic factors in diabetic C57BL/6J mice. Diabetes, 40(1), 82-87.
     連結：
168. Tan, M. J., Ye, J. M., Turner, N., Hohnen-Behrens, C., Ke, C. Q., Tang, C. P., et al. (2008). Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol, 15(3), 263-273.
     連結：
169. Tan, S. H., Dagvadorj, A., Shen, F., Gu, L., Liao, Z., Abdulghani, J., et al. (2008). Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res, 68(1), 236-248.
     連結：
170. Taylor, R. A., Toivanen, R., & Risbridger, G. P. (2010). Stem cells in prostate cancer: treating the root of the problem. Endocrine-Related Cancer, 17(4), R273-R285.
     連結：
171. Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2(6), 442-454.
     連結：
172. Thiery, J. P. (2003). Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol, 15(6), 740-746.
     連結：
173. Thiery, J. P., & Sleeman, J. P. (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol, 7(2), 131-142.
     連結：
174. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65(2), 87-108.
     連結：
175. Traish, A. M., Abdallah, B., & Yu, G. (2011). Androgen deficiency and mitochondrial dysfunction: implications for fatigue, muscle dysfunction, insulin resistance, diabetes, and cardiovascular disease. Horm Mol Biol Clin Investig, 8(1), 431-444.
     連結：
176. Vidal, O. M., Merino, R., Rico-Bautista, E., Fernandez-Perez, L., Chia, D. J., Woelfle, J., et al. (2007). In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Molecular Endocrinology, 21(1), 293-311.
     連結：
177. Vykhovanets, E. V., Shankar, E., Vykhovanets, O. V., Shukla, S., & Gupta, S. (2011). High-Fat Diet Increases NF-kappa B Signaling in the Prostate of Reporter Mice. Prostate, 71(2), 147-156.
     連結：
178. Walsh, K., & Perlman, H. (1997). Cell cycle exit upon myogenic differentiation. Current Opinion in Genetics & Development, 7(5), 597-602.
     連結：
179. Wang, W., Li, Y., Li, Y., Hong, A., Wang, J., Lin, B., et al. (2009). NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth. Int J Cancer, 124(3), 521-530.
     連結：
180. Wang, Y., Kreisberg, J. I., & Ghosh, P. M. (2007). Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets, 7(6), 591-604.
     連結：
181. Waters, D. L., Baumgartner, R. N., Garry, P. J., & Vellas, B. (2010). Advantages of dietary, exercise-related, and therapeutic interventions to prevent and treat sarcopenia in adult patients: an update. Clin Interv Aging, 5, 259-270.
     連結：
182. Wei, C., Willis, R. A., Tilton, B. R., Looney, R. J., Lord, E. M., Barth, R. K., et al. (1997). Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci U S A, 94(12), 6369-6374.
     連結：
183. Witting, L. A. (1983). Lipid Analysis, 2nd Edition, Isolation, Separation, Identification, and Structural-Analysis of Lipids - Christie,Ww. Journal of the American Oil Chemists Society, 60(7), 1240-1241.
     連結：
184. Wolf, D. A., Herzinger, T., Hermeking, H., Blaschke, D., & Horz, W. (1993). Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen. Mol Endocrinol, 7(7), 924-936.
     連結：
185. Wolk, A., Mantzoros, C. S., Andersson, S. O., Bergstrom, R., Signorello, L. B., Lagiou, P., et al. (1998). Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst, 90(12), 911-915.
     連結：
186. Wright, A. S., Thomas, L. N., Douglas, R. C., Lazier, C. B., & Rittmaster, R. S. (1996). Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest, 98(11), 2558-2563.
     連結：
187. Wu, Y., Zhao, W., Zhao, J., Pan, J., Wu, Q., Zhang, Y., et al. (2007a). Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology, 148(6), 2984-2993.
     連結：
188. Wu, Y., Zhao, W. D., Zhao, J. B., Pan, J. P., Wu, Q. Q., Zhang, Y. F., et al. (2007b). Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology, 148(6), 2984-2993.
     連結：
189. Xu, T. S., Shen, Y., Pink, H., Triantafillou, J., Stimpson, S. A., Turnbull, P., et al. (2004). Phosphorylation of p70(s6) kinase is implicated in androgen-induced levator ani muscle anabolism in castrated rats. Journal of Steroid Biochemistry and Molecular Biology, 92(5), 447-454.
     連結：
190. Xu, X. F., Zhou, S. W., Zhang, X., Ye, Z. Q., Zhang, J. H., Ma, X., et al. (2006). Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy. Asian J Androl, 8(4), 455-462.
     連結：
191. Yasui, Y., Hosokawa, M., Sahara, T., Suzuki, R., Ohgiya, S., Kohno, H., et al. (2005). Bitter gourd seed fatty acid rich in 9c,11t,13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells. Prostaglandins Leukot Essent Fatty Acids, 73(2), 113-119.
     連結：
192. Yeap, B. B., Krueger, R. G., & Leedman, P. J. (1999). Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology, 140(7), 3282-3291.
     連結：
193. Yuan, G. F., Chen, X. E., & Li, D. (2014). Conjugated linolenic acids and their bioactivities: a review. Food & Function, 5(7), 1360-1368.
     連結：
194. Zhang, M., Hettiarachchy, N. S., Horax, R., Chen, P., & Over, K. F. (2009). Effect of maturity stages and drying methods on the retention of selected nutrients and phytochemicals in bitter melon (Momordica charantia) leaf. J Food Sci, 74(6), C441-448.
     連結：
195. Zhou, Z. X., Lane, M. V., Kemppainen, J. A., French, F. S., & Wilson, E. M. (1995). Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol, 9(2), 208-218.
     連結：
196. Zhu, M. L., & Kyprianou, N. (2010). Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J, 24(3), 769-777.
     連結：
197. 林德岳. (2013). 山苦瓜萃取暨其酵素水解最佳化與三萜類成分之探討. 國立臺灣大學生命科學院生化科技學系.
     連結：
198. 董又慈. (2016). 山苦瓜改善高脂飲食誘發小鼠代謝異常、脂肪肝與肝相關基因mRNA表現. 國立臺灣大學生命科學院生化科技學系.
     連結：
199. 鄒尙瑀. (2016). 長期餵食山苦瓜對高脂飲食誘導肥胖小鼠代謝異常及白色脂肪組織褐化相關基因表現之效應. 國立臺灣大學生命科學院生化科技學系.
     連結：
200. Basch, E., Gabardi, S., & Ulbricht, C. (2003a). Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm, 60(4), 356-359.
201. Baserga, R., Porcu, P., Rubini, M., & Sell, C. (1993). Cell cycle control by the IGF-1 receptor and its ligands. Adv Exp Med Biol, 343, 105-112.
202. Frost, R. A., & Lang, C. H. (2003). Regulation of insulin-like growth factor-I in skeletal muscle and muscle cells. Minerva Endocrinol, 28(1), 53-73.
203. Hsing, A. W., Mclaughlin, J. K., Schuman, L. M., Bjelke, E., Gridley, G., Wacholder, S., et al. (1990). Diet, Tobacco Use, and Fatal Prostate-Cancer - Results from the Lutheran Brotherhood Cohort Study. Cancer Research, 50(21), 6836-6840.
204. Jia, L., Kim, J., Shen, H., Clark, P. E., Tilley, W. D., & Coetzee, G. A. (2003). Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res, 1(5), 385-392.
205. Laviola, L., Natalicchio, A., & Giorgino, F. (2007). The IGF-I signaling pathway. Current Pharmaceutical Design, 13(7), 663-669.
206. Liao, R. S., Ma, S., Miao, L., Li, R., Yin, Y., & Raj, G. V. (2013). Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. Transl Androl Urol, 2(3), 187-196.
207. Luke, M. C., & Coffey, D. S. (1994). Human androgen receptor binding to the androgen response element of prostate specific antigen. J Androl, 15(1), 41-51.
208. McCance, S. E. H. K. L. (2013). Understanding Pathophysiology. Elsevier Health Sciences.
209. Mori, M., Masumori, N., Fukuta, F., Nagata, Y., Sonoda, T., Miyanaga, N., et al. (2011). Weight gain and family history of prostate or breast cancers as risk factors for prostate cancer: results of a case-control study in Japan. Asian Pac J Cancer Prev, 12(3), 743-747.
210. Roberts, C. T., Jr. (2004). IGF-1 and prostate cancer. Novartis Found Symp, 262, 193-199; discussion 199-204, 265-198.
211. Schlueter, C., Weber, H., Meyer, B., Rogalla, P., Roser, K., Hauke, S., et al. (2005). Angiogenetic signaling through hypoxia - HMGB1: An angiogenetic switch molecule. American Journal of Pathology, 166(4), 1259-1263.
212. Xie, H., Huang, S., Deng, H., Wu, Z., & Ji, A. (1998). [Study on chemical components of Momordica charantia]. Zhong Yao Cai, 21(9), 458-459.
213. 呂侃霓. (2013). 以C57BL/6J小鼠模式研發血糖恆定之山苦瓜萃物. 國立臺灣大學生命科學院生化科技學系
214. 國家衛生研究院. (2003). 攝護腺癌診治共識.
215. 蔡豐隆. (2012). 山苦瓜萃取物經納豆菌NTU-18去醣基化作用之效果探討. 國立臺灣大學生命科學院生化科技學系.
216. 衛生福利部. (2015). 103年國人死因統計結果.
217. 穆偉倢. (2014). 山苦瓜上調C57BL/6J公鼠肝Fgf21 mRNA並誘發副睪脂褐化. 國立臺灣大學生命科學院生化科技學系.